Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cabazitaxel

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Cabazitaxel. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2020-000209-10 Sponsor Protocol Number: D8731C00002 Start Date*: 2020-10-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progr...
    Medical condition: Progressive Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003672-39 Sponsor Protocol Number: 1202-STBSG Start Date*: 2014-06-30
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma
    Medical condition: Locally advanced dedifferentiated liposarcoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073135 Dedifferentiated liposarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022064-12 Sponsor Protocol Number: EFC11784 Start Date*: 2011-03-23
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients wit...
    Medical condition: metastatic Castration Resistant Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) FI (Completed) DK (Completed) PT (Completed) IT (Completed) DE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000270-36 Sponsor Protocol Number: AbiCab Start Date*: 2015-05-07
    Sponsor Name:Umeå University Hospital
    Full Title: A randomized Phase II, open label multicenter cross-over study, to evaluate biomarkers, in 2nd line treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) with abiraterone and cabazit...
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003835-40 Sponsor Protocol Number: RG12-024 Start Date*: 2012-12-10
    Sponsor Name:University of Birmingham
    Full Title: A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with...
    Medical condition: Metastatic Castrate Refractory Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002296-18 Sponsor Protocol Number: CaTo-ROC Start Date*: 2015-07-30
    Sponsor Name:Vejle Hospital, Department of Oncology
    Full Title: Cabazitaxel in patients with Recurrent Ovarian Cancer after failure of standard therapy- A phase II trial
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002336-14 Sponsor Protocol Number: Start Date*: 2014-09-05
    Sponsor Name:University Hosptial Bristol NHS Foundation trust
    Full Title: A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis.
    Medical condition: Relapsed, locally advanced and/or metastatic carcinoma of the penis.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007384 Carcinoma in situ of penis PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004412-55 Sponsor Protocol Number: C.HO.SE. Start Date*: 2013-04-15
    Sponsor Name:AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
    Full Title: Cabazitaxel in relapsed high-risk HOrmone-SEnsitive prostate cancer patients. A multicentric Randomized phase II study. C.HO.SE. Trial
    Medical condition: Relapsed high-risk hormone-sensitive prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003498-27 Sponsor Protocol Number: JEVTCC-SOGUG-2011-04 Start Date*: 2011-12-19
    Sponsor Name:Grupo Español de Tratamiento de Tumores Genitourinarios (SOGUG)-Spanish Genitourinary Oncologic Group
    Full Title: A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed ?12 months after a previous platinum based chemo...
    Medical condition: advanced or metastatic transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000286-36 Sponsor Protocol Number: IGR2012/1950 Start Date*: 2014-04-02
    Sponsor Name:Gustave Roussy
    Full Title: A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors
    Medical condition: patients with pre-treated metastatic and /or primary mediastinal non-seminomatous germ-cell tumors
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001550-98 Sponsor Protocol Number: C-GBM(XRP6258) Start Date*: 2013-10-04
    Sponsor Name:University Hospital of Ulm
    Full Title: Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM) - The C-GBM Study -
    Medical condition: •Patients with diagnosis glioblastoma multiforme (GBM) WHO grade IV ; •Progression during or within 6 months after last temozolomide treatment; •Time since last temozolomide > 21 days
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001218-32 Sponsor Protocol Number: RLL-CAB-2011-01 Start Date*: 2012-06-14
    Sponsor Name:Rafael López López
    Full Title: Randomized phase II b study of Cabazitaxel in metastatic Colorectal Cancer resistant to standard treatment
    Medical condition: Metastatic colorectal cancer resistant to standard treatment.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001224-35 Sponsor Protocol Number: TaxOvar Start Date*: 2012-08-13
    Sponsor Name:Vejle Hospital
    Full Title: Cabazitaxel in platinum refractory ovarian cancer. A phase II trial
    Medical condition: Platinum refractory ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001179-60 Sponsor Protocol Number: CABASTY Start Date*: 2019-10-21
    Sponsor Name:A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie)
    Full Title: Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 70 years) with metastatic castration-resi...
    Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)
    Disease:
    Population Age: Elderly Gender: Male
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002552-16 Sponsor Protocol Number: RRK4368 Start Date*: 2012-11-29
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy.
    Medical condition: Transitional cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10061620 Adenocarcinoma with transitional cell carcinoma of bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001591-35 Sponsor Protocol Number: ASST-ONCO-CABAC2017 Start Date*: 2017-12-27
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Multicenter, prospective, non-randomized, phase II trial designed to evaluate the activity of Cabazitaxel in patients with advanced Adreno-Cortical- Carcinoma progressing after previous chemotherap...
    Medical condition: Histologically confirmed diagnosis of ACC Locally advanced or metastatic disease not amenable to radical surgery resection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061588 Adrenal neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002429-12 Sponsor Protocol Number: UC_0160/1613 Start Date*: 2018-01-31
    Sponsor Name:UNICANCER
    Full Title: PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY
    Medical condition: Metastatic castrate-resistant prostate cancer requiring initiation of chemotherapy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004676-29 Sponsor Protocol Number: LPS14201 Start Date*: 2015-07-22
    Sponsor Name:Sanofi-aventis Groupe
    Full Title: A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)- targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who...
    Medical condition: prostate cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed) BE (Completed) NL (Completed) IE (Completed) GR (Completed) FR (Completed) IS (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001361-27 Sponsor Protocol Number: ICR-CTSU/2015/10054 Start Date*: 2016-09-21
    Sponsor Name:The Institute of Cancer Research
    Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005251-25 Sponsor Protocol Number: CABACARE Start Date*: 2017-04-07
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, p...
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 17 06:05:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA